|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.
|
|
 |
|
Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….
|
|
 |
|
Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……
|
|
 |
|
Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin highlights innovations from key players in parenteral delivery and prefilled syringes, with focuses on safety, meeting regulatory requirements, cost, fill/finish, and dosing.
|
|
|
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
|
|
|
Gregor Deutschle says by implementing a strategic, considerate, and proactive approach to trend forecasting, pharmaceutical service providers can effectively weigh the benefits and challenges of potential trends, invest in those most aligned with customer needs, and avoid the allocation of time and resources in trends that will not provide meaningful ROI.
|
|
|
|
|
|
|
|
|

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists at the University of Kansas’ Higuchi Biosciences Center, for specific use in drug development and formulation. This unique technology has enabled 15 FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter International’s Nexterone, Acrotech Biopharma L.L.C.’s and CASI Pharmaceuticals’ Evomela, Melinta Therapeutics’ Baxdela, Pfizer’s VFEND IV and Sage Therapeutics’ Zulresso. The most recent approval in March 2023 was Novartis’ MEKINIST, a pediatric oral product. There are many Captisol-enabled products currently in various stages of development. Click here for more.

Click image to see Serán Bioscience’s latest video
latest video

|
|
|
|
|
|
 |
|
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
|
|
 |
|
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
|
|
|
|
|
|
|
|
 |
|
Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.
Download our latest white paper, jointly authored with MeltPrep, to …
|
|
 |
|
Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug performance.
Our latest whitepaper delves into the impact of POLYOX™ PEO (Polyethylene Oxide) on drug …
|
|
 |
|
The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …
|
|
|
|
|
Upcoming eNewsletter Features:
April 23 – Particle Design Technology
April 30 – Controlled Release
|
|
|
|
|
|
|
|